tiprankstipranks
Trending News
More News >
Inoviq Ltd (AU:IIQ)
ASX:IIQ

Inoviq Ltd (IIQ) AI Stock Analysis

Compare
1 Followers

Top Page

AU

Inoviq Ltd

(Sydney:IIQ)

Rating:43Neutral
Price Target:
AU$0.50
▲(35.14%Upside)
Inoviq Ltd's overall score is primarily driven by significant financial performance challenges, particularly in profitability despite revenue growth. Technical analysis suggests mixed signals with potential oversold conditions. Valuation is weak due to negative earnings and lack of dividends. These factors together reflect a cautious outlook for the stock.

Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)

Inoviq Ltd Business Overview & Revenue Model

Company DescriptionInoviq Ltd (IIQ) is a biotechnology company specializing in the development and commercialization of diagnostic and prognostic products for cancer and other diseases. The company operates in the healthcare sector, focusing on providing innovative solutions that improve patient outcomes through early detection and monitoring of diseases. Inoviq's core products include a range of diagnostic tests that leverage proprietary technologies to offer high accuracy and reliability in clinical applications.
How the Company Makes MoneyInoviq Ltd generates revenue primarily through the sale of its diagnostic and prognostic products to healthcare providers, clinical laboratories, and other medical institutions. The company may also earn income from licensing its proprietary technologies to third parties and entering into strategic partnerships or collaborations with other firms in the biotechnology and healthcare sectors. These partnerships can involve co-development agreements, where Inoviq provides technology or expertise in exchange for milestone payments, royalties, or a share of revenue from jointly developed products. Additionally, the company may receive grants or funding from governmental or non-governmental organizations to support research and development projects.

Inoviq Ltd Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue535.12K398.19K276.75K468.10K535.10K
Gross Profit-989.82K-1.04M220.30K404.05K-149.80K
EBITDA-6.63M-9.02M-5.67M-6.05M0.00
Net Income-6.55M-8.97M-6.51M-12.37M-3.25M
Balance Sheet
Total Assets21.71M21.51M30.78M33.52M7.37M
Cash, Cash Equivalents and Short-Term Investments9.23M7.81M15.39M5.00M7.33M
Total Debt403.74K730.71K998.69K1.26M0.00
Total Liabilities1.72M1.89M2.49M4.46M899.12K
Stockholders Equity19.99M19.62M28.29M29.06M6.48M
Cash Flow
Free Cash Flow-4.50M-7.32M-6.47M-6.05M-2.54M
Operating Cash Flow-4.32M-7.02M-6.06M-5.26M-2.54M
Investing Cash Flow-174.34K-292.27K-411.90K2.64M0.00
Financing Cash Flow5.91M-267.98K16.87M286.48K2.31M

Inoviq Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.37
Price Trends
50DMA
0.40
Negative
100DMA
0.40
Negative
200DMA
0.44
Negative
Market Momentum
MACD
-0.01
Positive
RSI
40.56
Neutral
STOCH
14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IIQ, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.40, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.56 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IIQ.

Inoviq Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
HK$15.37B5.69-7.44%4.08%11.55%-28.15%
AUBDX
46
Neutral
AU$24.15M-104.23%-17.26%
AUBDX
46
Neutral
AU$24.15M-104.23%-17.26%
AUGSS
45
Neutral
AU$82.91M-47.52%44.61%16.40%
AURHY
44
Neutral
AU$18.29M-71.10%76.17%
AURHY
44
Neutral
AU$18.29M-71.10%76.17%
AUIIQ
43
Neutral
AU$41.30M-39.07%26.07%0.85%
AULDX
43
Neutral
AU$20.96M-51.49%80.84%57.59%
AULDX
43
Neutral
AU$20.96M-51.49%80.84%57.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IIQ
Inoviq Ltd
0.36
-0.20
-35.71%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.07
-50.00%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.07
-50.00%
AU:RHY
Rhythm Biosciences Ltd.
0.06
0.00
0.00%
AU:RHY
Rhythm Biosciences Ltd.
0.06
0.00
0.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.03
-0.01
-25.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.03
-0.01
-25.00%
AU:GSS
Genetic Signatures Ltd.
0.36
-0.36
-50.00%

Inoviq Ltd Corporate Events

INOVIQ’s New Cancer Treatment Shows Promising Lab Results
Jun 23, 2025

INOVIQ Limited has announced that its new cancer treatment, CAR-NK-EVs, has demonstrated the ability to kill 88% of breast and lung cancer cells in laboratory tests. This advancement highlights the potential of INOVIQ’s exosome platform to offer a more efficient, safer, and potentially more effective alternative to traditional CAR-T therapies. The announcement underscores the company’s commitment to advancing cancer treatment options and may enhance its positioning within the biotechnology sector.

INOVIQ’s Breakthrough Cancer Treatment Shows 88% Efficacy in Lab Tests
Jun 17, 2025

INOVIQ Ltd has announced a significant breakthrough in its exosome therapeutic program, with lab tests showing that its new cancer treatment kills 88% of triple-negative breast cancer and lung cancer cells. This innovative treatment uses engineered immune cell particles, CAR-NK-EVs, which target and kill cancer cells more precisely. The treatment could potentially be faster, safer, and more effective than traditional therapies, offering an ‘off-the-shelf’ solution that could benefit many patients. The next step involves testing in animal models before progressing to human clinical trials, marking a promising advancement in cancer treatment options.

Inoviq Ltd Trading Suspension Lifted Amid ASX Compliance Enquiries
Jun 2, 2025

Inoviq Ltd has announced that the suspension of its securities trading will be lifted following the release of further disclosure related to a recent price query. The Australian Securities Exchange (ASX) is continuing its enquiries into Inoviq’s compliance with listing rules, which may impact the company’s market operations and investor confidence.

INOVIQ’s Breakthrough in Early Ovarian Cancer Screening
Jun 2, 2025

INOVIQ Limited has announced significant results from its EXO-OC™ ovarian cancer test, presented at the American Society of Clinical Oncology Annual Meeting. The test achieved 77% sensitivity and 99.6% specificity in detecting ovarian cancer across all stages, with no missed early-stage diagnoses. This breakthrough positions INOVIQ as a leader in exosome technology, addressing the critical unmet need for early detection of ovarian cancer. The company plans to further develop and commercialize the test, seeking regulatory approval and aiming to launch it as a Laboratory Developed Test in the US, potentially saving lives by enabling earlier diagnosis and intervention.

Inoviq Ltd Securities Suspended from ASX Quotation
May 28, 2025

Inoviq Ltd’s securities have been suspended from quotation on the ASX following a trading halt initiated on May 26, 2025. The suspension is due to the need for further disclosure regarding issues highlighted in the company’s price query response, and will remain until ASX confirms compliance with its Listing Rules.

INOVIQ Clarifies ASX Query and Highlights Upcoming ASCO Presentation
May 28, 2025

INOVIQ Limited responded to an ASX price query by clarifying that the recent abstract published by the American Society of Clinical Oncology (ASCO) does not contain new, price-sensitive information beyond what was previously disclosed. However, the company highlighted the upcoming ASCO Annual Meeting presentation as potentially price-sensitive, emphasizing its confidentiality due to an ongoing patent application process. The company is adhering to ASCO’s strict embargo policies to avoid reputational and commercial risks, and it is ensuring compliance with listing rules while protecting its intellectual property.

INOVIQ Ltd Requests Trading Halt Pending Key Announcement
May 26, 2025

INOVIQ Ltd has requested a trading halt on its securities pending an announcement related to an ASX Price Query response. The halt will remain in effect until the company releases the announcement or until normal trading resumes on 28 May 2025. This move is part of the company’s compliance with ASX listing rules and aims to ensure transparency and proper dissemination of information to stakeholders.

Inoviq Ltd Announces Cessation of Securities
May 1, 2025

Inoviq Ltd has announced the cessation of 166,667 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could influence investor perception regarding the company’s ability to meet certain conditions tied to its securities.

INOVIQ Advances Exosome Programs and Expands Global Reach
Apr 30, 2025

INOVIQ Limited has made significant advancements in its exosome programs, including expanding its customer base for the EXO-NET technology across Europe, the US, and Asia, and developing AI-enhanced algorithms for early ovarian cancer detection. The company has also engaged the Peter MacCallum Cancer Centre to validate its CAR-exosome therapy for triple-negative breast cancer and published diagnostic performance results for its neuCA15-3 test. Additionally, INOVIQ has established a Medical and Scientific Advisory Board and appointed Dr. Emma Ball as Chief Commercial Officer. These developments are expected to enhance INOVIQ’s industry positioning and offer new therapeutic options for cancer patients.

Inoviq Ltd Issues Unquoted Equity Securities to Employees
Apr 9, 2025

Inoviq Ltd has announced the issuance of 150,000 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 20, 2025